Stockscreener 앱 받기
38.51
1.72%
0.65
시간 외 거래:
38.93
0.42
+1.09%
전일 마감가:
$37.86
열려 있는:
$37.89
하루 거래량:
2.46M
Relative Volume:
0.75
시가총액:
$5.91B
수익:
-
순이익/손실:
$-284.08M
주가수익비율:
-15.89
EPS:
-2.4234
순현금흐름:
$-234.65M
1주 성능:
-3.48%
1개월 성능:
-0.95%
6개월 성능:
+219.06%
1년 성능:
+354.66%
1일 변동 폭
$37.71
$39.65
1주일 범위
$36.01
$40.40
52주 변동 폭
$3.72
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.51 | 5.81B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Cogent Biosciences announcse U.S. BTD for bezuclastinib - Yahoo Finance
Cogent Biosciences Gains Breakthrough Therapy Designation For Bezuclastinib Combination In GIST - Nasdaq
(COGT) Risk Channels and Responsive Allocation - Stock Traders Daily
Cogent Biosciences stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com UK
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag - Benzinga
Cogent Biosciences (COGT) Gains FDA Breakthrough Therapy Designa - GuruFocus
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - The Manila Times
New GIST combo cuts progression risk by 50% in Cogent trial - Stock Titan
Retail Surge: What is the long term forecast for Cogent Biosciences Inc stockJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT) - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial - TipRanks
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares - MarketBeat
Fairmount funds sells Cogent Biosciences (COGT) shares worth $127.4 million - Investing.com Canada
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib ComboHas The Bull Case Changed? - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (C - GuruFocus
Cogent Biosciences Initiates New Drug Application Submission for Bezuclastinib Under Real-Time Oncology Review - marketscreener.com
FDA Greenlights Cogent Biosciences' New Drug Application for GIS - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - The Manila Times
Cancer drug combo cuts GIST progression risk by 50% in key trial - Stock Titan
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT - MarketBeat
What makes Cogent Biosciences Inc. stock attractive todayQuarterly Profit Review & Expert Verified Movement Alerts - bollywoodhelpline.com
HC Wainwright is bullish on Cogent Biosciences, Inc. (COGT) - MSN
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - Sahm
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network
Cogent Biosciences : COGT JPM 26 FINAL - marketscreener.com
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - MSN
Cogent Biosciences Announces Anticipated 2026 Commercial - GlobeNewswire
Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Finviz
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge - AOL.com
Cogent Biosciences announces proposed concurrent public offerings - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cogent Biosciences Inc. stock a buy for dividend growthDurability and Wear Notes & lightweight options for faster days - ulpravda.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews
Cogent Bio surges after late-stage trial data for lead drug - MSN
A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat
Aug Ideas: Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Profit Summary & Community Consensus Trade Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform growth indexesQuarterly Growth Report & Precise Entry and Exit Recommendations - Улправда
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):